December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Proof-of-concept phase I data for mitapivat, an oral, small molecule inhibitor of pyruvate kinase R, shows early evidence of efficacy and safety in patients with stable sickle cell disease.